



Certification Under 37 CFR 1.97(e)

Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

Copies of the cited references are enclosed.

A copy of the cited reference (AA) was submitted in prior application, U.S. Serial No. 08/617,737. Another copy is not enclosed herewith.

The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

Concise Explanation Requirement (non-English references):

The "concise explanation" requirement for reference(s) \_\_\_\_\_ under 37 CFR 1.98(a)(3) is satisfied by:

the explanation provided on the attached sheet.

the explanation provided in the Specification.

submission of the enclosed International Search Report.

the enclosed English language abstract.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

Enclosed is a check in the amount of \$ \_\_\_\_\_.

Please charge Deposit Account 08-0380 in the amount of \$ \_\_\_\_\_.

A copy of this Statement is enclosed.

Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Helen Lee  
Helen Lee  
Attorney for Applicants  
Registration No.: 39,270  
Telephone: (781) 861-6240  
Facsimile: (781) 861-9540

Lexington, Massachusetts 02173  
Dated: November 26, 1997

KIR921A3.A9A  
HL18/WP51  
CSE/HL  
11/26/97



Gau 1806  
10  
PATENT APPLICATION  
DOCKET NO.: KIR92-01A3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann, Ravinder N. Maini and Richard O. Williams

Application No.: 08/607,419 Group Art Unit: 1806

Filed: February 28, 1996 Examiner: P. Gabel

Title: TREATMENT OF TUMOR NECROSIS FACTOR MEDIATED DISEASES

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

on 11/26/97

LISA JENSEN

Date Signature

Lisa Jensen

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
DEC 05 1997  
GROUP 1800

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or  
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

under 37 CFR 1.97(c) together with either:

a Certification under 37 CFR 1.97(e), as checked below, or

a \$240.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Certification under 37 CFR 1.97(e), as checked below, and

a Petition under 37 CFR 1.97(d)(2), and

a \$130.00 petition fee set forth in 37 CFR 1.17(i).  
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant requests that the attached IDS and cited reference(s) \_\_\_\_\_  
be placed in the application filewrapper.  
(Filed after payment of issue fee)